Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 2/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21823767 | 1.00 | EIF4E (0.44) | EIF4EF2RL3ARCYP19A1 | |
| SCHEMBL21823780 | 0.78 | F2RL3 (0.45) | F2RL3CYP19A1 | |
| SCHEMBL21823779 | 0.78 | F2RL3 (0.45) | F2RL3CYP19A1 | |
| SCHEMBL21823765 | 0.78 | F2RL3 (0.40) | EIF4EF2RL3CYP19A1 | |
| SCHEMBL21823783 | 0.71 | CYP19A1 (0.56) | CYP19A1 | |
| SCHEMBL19149456 | 0.71 | ILK (0.46) | AR | |
| SCHEMBL23320376 | 0.65 | NPC1 (0.59) | AR | |
| SCHEMBL21823820 | 0.65 | CYP19A1 (0.56) | CYP19A1 | |
| SCHEMBL7088513 | 0.64 | ALDH1A1 (0.44) | AR | |
| SCHEMBL5834641 | 0.64 | RAB9A (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | EIF4E 2438/4885F2RL3 3912/4885AR 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.